CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 22 pages
Work group considerations and clinical considerations for clesrovimab Maternal and Pediatric RSV Session Coronavirus and Other Respiratory Viruses Division June 25, 2025U.S. Centers for Disease Control and Prevention •Work group considerations and interpretations of uptake, safety, effectiveness, and impact studies •Review of clinical considerations -Clesrovimab recommendations compared with nirsevimab -Clesrovimab storage, handling, and administrationOutline 2 •Nirsevimab was effective…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 2 pages
U.S. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Influenza Session —Introduction Dr. Vivien Dugan Influenza Division, CDC/NCIRD June 26, 2025 Flublok (recombinant influenza vaccine) in older children and …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 30 pages
VAP00027 Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years For the Advisory Committee of Immunization Practices (ACIP) Influenza Working Group MAT-US-2504669 P v3.0 EXP 28 APR 2026Pedro Folegatti – Global Clinical Development Director (Presenter) Thinus Marais – Medical Head: Influenza & COVID, Vaccines North America Presenter’s disclosures Pedro Folegatti , MD DTM&H MSc Dphil is a…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 17 pages
Severity, Disease Burden, and Prevented Burden for the 2024 -2025 Influenza Season Influenza Division, CDC 2024 -2025 Influenza Season News Influenza Severity Assessment by Season and by Age Group Severity Classification by Age Group Influenza Season* 0-17 years 18-64 years ≥65 years All Ages 2009- 2010 Very High Moderate Low Moderate 2010- 2011 Moderate Moderate Moderate Moderate 2011- 2012 Low Low Low Low 2012- 2013 Moderate Moderate High Moderate 2013- 2014 Moderate Moderate Moderate…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 14 pages
U.S. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. 2024 -25 Influenza Season Update and Seasonal Influenza Vaccine Recommendations for the 2025 -26 U.S. Influenza Season Dr. Vivien Dugan Influenza Division,…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 20 pages
ACIP 2025 BusinessThimerosal as a Vaccine Preservative Prepared for the Advisory Committee for Immunization PracticesLyn Redwood RN, MSN, FP (Retired) 2The Food and Drug Administration Modernization Act of 1997 •Compiled list of drugs and foods that contained intentionally introduced mercury compounds •Provided quantitative and qualitative analysis of mercury compounds •Report included 219 products which included 11 biologics and immunoglobulin therapies Ref: U.S. Congress. (1997,…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 37 pages
Partial Evidence to Recommendations for use of chikungunya vaccines among persons in U.S. territories at risk for chikungunya virus transmissionNational Center for Emerging and Zoonotic Infectious Diseases Dr. Lyle Petersen Director, Division of Vector -Borne Diseases Advisory Committee on Immunization Practices meeting June 26, 2025 •Two licensed chikungunya vaccines -Live attenuated vaccine licensed in November 2023 for use in persons aged ≥18 years (manufactured by Valneva) -Virus…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 4 pages
Introduction to the Anthrax Vaccine Work Group Brendan Jackson, MD, MPH Captain, U.S. Public Health Service Principal Deputy Director Division of High -Consequence Pathogens and Pathology June 26, 2025 Advisory Committee on Immunization PracticesNational Center for Emerging and Zoonotic Infectious Diseases •Bacillus anthracis , the causative agent of anthrax, is an endospore -forming bacterium found naturally in soil around the world •Humans are most often infected by exposure to infected…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 12 pages
1 MMRV Vaccine Safety Contents Summary ................................ ................................ ................................ ................................ ...... 1 Cochrane Review ................................ ................................ ................................ ........................... 2 General safety ................................ ................................ ................................ ............................... 3 Febrile…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 13 pages
MMRV MMRV = One combined shot for Measles, Mumps, Rubella and Varicella alternative to MMR+V = Two shots, one for Measles, Mumps and Rubella and another for Varicella No known difference in efficacy MMRV Timeline 2005: FDA licensed the combined MMRV vaccine for use in children 12 months to 12 years of age. 2006: The CDC Advisory Committee on Immunization Practices recommended use of MMRV, with preference over separate MMR and Varicella vaccines. Weekly Safety Surveillance CDC’s…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 23 pages
Agency for Toxic Substances and Disease Registry National Center for Environmental Health Centers for Disease Control and Prevention Mpox Vaccine Work Group Faisal Syed Minhaj, PharmD, MPH Poxvirus and Rabies Branch Centers for Disease Control and Prevention ACIP Meeting April 15, 2025 •Genus: Orthopoxvirus •Family: Poxviridae •Discovered in 1958 after two pox-like disease outbreaks in research monkey colonies •Specific animal reservoir unknown, but likely African small mammals •On…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 26 pages
! "# " $%$& ' ( ) * +,- ., / 0 * &/ ( $ , / 1 2 3 $& ' 4 &$)5 6 -. &2) 4 &$/ 7$ 88 &$/ - *9 :; <
;= > ? @ ; A: ;;
;; ; B ;…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 56 pages
Agency for Toxic Substances and Disease Registry National Center for Environmental Health Centers for Disease Control and Prevention Evidence to Recommendations Framework: Vaccination with Jynneos for Adolescents at Risk of Mpox During Outbreaks Faisal Syed Minhaj, PharmD, MPH Poxvirus and Rabies Branch Centers for Disease Control and Prevention Advisory Committee on Immunization Practices April 15, 2025 •Structure to describe information considering in moving fr om evidence to ACIP…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 41 pages
Agency for Toxic Substances and Disease Registry National Center for Environmental Health Centers for Disease Control and Prevention Evidence to Recommendations Framework: Routine Vaccination with Jynneos for Adolescents at Risk of Mpox Faisal Syed Minhaj, PharmD, MPH Poxvirus and Rabies Branch Centers for Disease Control and Prevention Advisory Committee on Immunization Practices April 15, 2025 Does ACIP recommend vaccination* with the 2-dose †JYNNEOS vaccine series for persons aged…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 7 pages
Introduction to the Lyme Disease Vaccines Work Group Grace E. Marx, MD, MPH Lead, Lyme Disease Vaccines Work Group April 15, 2025 Advisory Committee on Immunization PracticesNational Center for Emerging and Zoonotic Infectious Diseases •Most common vector -borne disease in the U.S. •An estimated 476,000 people in the U.S. diagnosed and treated for Lyme disease each year1 •Estimated to cost $345– 968 million annually in health care costs2Public Health Problem –Lyme disease 1. Kugeler K et…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2019
Lisa Jenkins · DIVISION OF BASIC SCIENCES - NCI · 2019 · $418,689 — Overall, the expertise of the Mass Spectrometry Unit is being widely used to further the research of multiple groups within the NIH. In FY2019, the unit collaborated in 67 different projects, with more than 3000 samples processed and analyzed. These projects are being performed in collaboration with…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2019
Pamela J Bjorkman · CALIFORNIA INSTITUTE OF TECHNOLOGY · 2019 · $410,750 — Summary The rapid mutation rate of HIV-1 results in many thousands of viral strains, thus thwarting current vaccine efforts. Although HIV-1 infection can be controlled by anti-retroviral therapy (ART), the virus rebounds within weeks of ART cessation because complete elimination of HIV-1 is prevente…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2019
HEATHER R DESAIRE · UNIVERSITY OF KANSAS LAWRENCE · 2019 · $671,763 — DESCRIPTION (provided by applicant): Preventing human immunodeficiency virus (HIV-1) transmission by vaccination is a highly desirable, but elusive, goal. Vaccine-induced antibodies that bind the HIV-1 envelope glycoprotein (Env) spike and neutralize the virus are thought to be a desirable comp…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2019
JANICE P EVANS · PURDUE UNIVERSITY · 2019 · $77,500 — PROJECT SUMMARY Actin cytoskeleton-based processes play crucial roles in meiosis in mammalian oocytes, including positioning of the meiotic spindle and asymmetric cell division. These events in oocytes are essential for reproductive success, as gene knockouts that impair these processes cause femal…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2019
Vaughn Vasil Smider · APPLIED BIOMEDICAL SCIENCE INSTITUTE · 2019 · $359,955 — Vaccines are the primary means by which to prevent, control, or eradicate infectious diseases. While many vaccines have been successfully developed and have resulted in enormous medical and veterinary benefit, there are certain viruses that have eluded effective vaccine development. Generally, virus…